Coverage
-
March 03, 2017
Biosimilar makers must satisfy each step of the Biologics Price Competition and Innovation Act's "patent dance" if they hope to reduce damages that innovator companies can seek for infringement, a Massachusetts federal judge said in a newly released opinion.
11 other articles on this case.
View all »